Molecules with extended half-lives, compositions and uses thereof
CA 2431600 C · Owner: Medimmune, Llc · Inventors: Dall'Acqua, William; Johnson, Leslie S.; Ward, Elizabeth Sally
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides molecules including IgGs, non-IgG , immunoglobulins proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain or a portion thereof , that binds the FcRn having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic prophylactic or , diagnostic use of such molecules.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 12, 2001 and granted April 17, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 12, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 12, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.